Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors.
作者信息
Gouda M A, Hu M I, Cabanillas M E, Wu J, Meric-Bernstam F, Subbiah V
机构信息
Departments of Investigational Cancer Therapeutics.
Departments of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston.
出版信息
Ann Oncol. 2023 Oct;34(10):946-948. doi: 10.1016/j.annonc.2023.07.002. Epub 2023 Jul 19.
Abstract
摘要
相似文献
1
Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors.
Ann Oncol. 2023 Oct;34(10):946-948. doi: 10.1016/j.annonc.2023.07.002. Epub 2023 Jul 19.
2
Selective RET kinase inhibition for patients with RET-altered cancers.
Ann Oncol. 2018 Aug 1;29(8):1869-1876. doi: 10.1093/annonc/mdy137.
3
Precious Gene: The Application of RET-Altered Inhibitors.
Molecules. 2022 Dec 13;27(24):8839. doi: 10.3390/molecules27248839.
4
Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.
J Med Chem. 2024 Mar 28;67(6):4346-4375. doi: 10.1021/acs.jmedchem.3c02319. Epub 2024 Mar 14.
5
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Clin Cancer Res. 2021 Jan 1;27(1):34-42. doi: 10.1158/1078-0432.CCR-20-2278. Epub 2020 Oct 20.
6
Towards precision oncology in RET-aberrant cancers.
Cell Cycle. 2017 May 3;16(9):813-814. doi: 10.1080/15384101.2017.1302235. Epub 2017 Mar 20.
7
Targeting RET alterations in non-small cell lung cancer.
Curr Probl Cancer. 2024 Apr;49:101074. doi: 10.1016/j.currproblcancer.2024.101074. Epub 2024 Mar 16.
8
Hallmarks of RET and Co-occuring Genomic Alterations in -aberrant Cancers.
Mol Cancer Ther. 2021 Oct;20(10):1769-1776. doi: 10.1158/1535-7163.MCT-21-0329. Epub 2021 Sep 6.
9
How should "RET positive" NSCLC be treated?
Lung Cancer. 2017 Jun;108:250-251. doi: 10.1016/j.lungcan.2017.02.006. Epub 2017 Feb 6.
10
REToma: a cancer subtype with a shared driver oncogene.
Carcinogenesis. 2020 Apr 22;41(2):123-129. doi: 10.1093/carcin/bgz184.
引用本文的文献
1
Early Weight Gain as a Risk Factor for Increased Maximum Weight Gain Among Patients With NSCLC on Lorlatinib and Other ALK Tyrosine Kinase Inhibitors.
JTO Clin Res Rep. 2025 Jun 30;6(9):100870. doi: 10.1016/j.jtocrr.2025.100870. eCollection 2025 Sep.
2
Systemic therapies for medullary thyroid carcinoma: state of the art.
Ther Adv Endocrinol Metab. 2025 May 11;16:20420188251336091. doi: 10.1177/20420188251336091. eCollection 2025.
3
Overview of management and therapeutic advances in medullary thyroid cancer.
Endocr Oncol. 2025 Mar 11;5(1):e240077. doi: 10.1530/EO-24-0077. eCollection 2025 Jan.
4
Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model.
Cancer Lett. 2025 Jan 6;611:217444. doi: 10.1016/j.canlet.2025.217444.
5
Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch.
NPJ Precis Oncol. 2024 Jul 31;8(1):167. doi: 10.1038/s41698-024-00659-x.
本文引用的文献
1
Analysis of Serious Weight Gain in Patients Using Alectinib for ALK-Positive Lung Cancer.
J Thorac Oncol. 2023 Aug;18(8):1017-1030. doi: 10.1016/j.jtho.2023.03.020. Epub 2023 Mar 29.
2
Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist.
Cell Metab. 2023 Feb 7;35(2):274-286.e10. doi: 10.1016/j.cmet.2022.12.011. Epub 2023 Jan 10.
3
Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy.
J Thorac Oncol. 2022 Sep;17(9):1130-1136. doi: 10.1016/j.jtho.2022.06.008. Epub 2022 Jul 2.
4
Precision therapy for RET-altered cancers with RET inhibitors.
Trends Cancer. 2021 Dec;7(12):1074-1088. doi: 10.1016/j.trecan.2021.07.003. Epub 2021 Aug 12.
5
GDF15/GFRAL Pathway as a Metabolic Signature for Cachexia in Patients with Cancer.
J Cancer. 2021 Jan 1;12(4):1125-1132. doi: 10.7150/jca.50376. eCollection 2021.
6
Antibody-mediated inhibition of GDF15-GFRAL activity reverses cancer cachexia in mice.
Nat Med. 2020 Aug;26(8):1264-1270. doi: 10.1038/s41591-020-0945-x. Epub 2020 Jul 13.
7
Characterization of on-target adverse events caused by TRK inhibitor therapy.
Ann Oncol. 2020 Sep;31(9):1207-1215. doi: 10.1016/j.annonc.2020.05.006. Epub 2020 May 15.
8
Targeting both sides of the GDF15-GFRAL-RET receptor complex: A new approach to achieve body weight homeostasis.
Genes Dis. 2017 Nov 21;4(4):183-184. doi: 10.1016/j.gendis.2017.11.004. eCollection 2017 Dec.
9
The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases.
Cell Metab. 2018 Sep 4;28(3):353-368. doi: 10.1016/j.cmet.2018.07.018.
Zotero 插件